How doctors providing oral cancer medications affects patients with advanced prostate cancer
Physician dispensing of oral specialty drugs for advanced prostate cancer and its implications for patients
This study is looking at how giving advanced prostate cancer patients their medications directly from their doctors' offices can make it easier for them to get and stick to their treatments, while also checking if this approach helps improve their health outcomes.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Michigan at Ann Arbor NIH-funded |
| Lab location | 1 site (Ann Arbor, United States) |
| Project ID | NIH-11240115 on NIH RePORTER |
What this research studies
This research investigates the impact of physicians dispensing oral specialty drugs directly to patients with advanced prostate cancer. By allowing urologists and oncologists to provide medications in their offices, the study aims to improve patient access and adherence to treatments like abiraterone and enzalutamide. The research will explore both the benefits of this delivery model and the potential financial incentives that may influence prescribing practices. Ultimately, it seeks to understand how these changes affect patient outcomes and treatment efficacy.
Who could benefit from this research
Good fit: Ideal candidates for this research are men diagnosed with advanced prostate cancer who are prescribed oral specialty drugs.
Not a fit: Patients with early-stage prostate cancer or those not receiving oral specialty drugs may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could enhance the way advanced prostate cancer is treated, leading to better patient access to effective medications and improved health outcomes.
How similar studies have performed: Previous research has shown that similar approaches to medication delivery can improve patient adherence and outcomes, suggesting potential success for this study.
Where this research is happening
Ann Arbor, United States
- University of Michigan at Ann Arbor — Ann Arbor, United States (Active)
Researchers
- Principal investigator: Hollenbeck, Brent K. — University of Michigan at Ann Arbor
- Study coordinator: Hollenbeck, Brent K.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.